VC and Investment
Biotechnology
US biotech major Moderna plans to raise $2 billion through a private placement of convertible senior notes due 2032, offered to qualified institutional buyers under Rule 144A. Initial purchasers will get a 13-day option to take up to $300 million of additional notes, which would lift the total to $2.3 billion. 28 August 2026
Today's issue
Refine search
Pharmaceutical
Karyopharm Therapeutics today reported top-line results from its Phase III SENTRY Trial in myelofibrosis that met the first co-primary endpoint, demonstrating statistically-significant improvement in spleen reduction volume. 24 March 2026
Pharmaceutical
.Swiss pharma major Novartis is committing more than 3.3 billion yuan ($480 million) to expand its footprint in China, deepening a strategic shift toward local innovation and manufacturing as the country cements its role as a key growth engine. 24 March 2026
Biotechnology
UK-based Immutrin, a biotech developing next generation antibody therapy to reverse amyloidosis, has successfully raised £65 million ($87 million) in a Series A financing. 24 March 2026
Biotechnology
USA-based Oryon Cell Therapies, a biotech developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, has emerged from stealth and closed a new $21 million tranche of its Series A financing. 23 March 2026
Biotechnology
AI-driven biotech Earendil Labs has secured $787 million in financing to expand its biologics pipeline and internal R&D capabilities, with backing from Sanofi and a biotech fund created by Pfizer, among others. 23 March 2026
Biotechnology
USA-based immunotherapy specialist SAB Biotherapeutics has announced the closing of an underwritten public offering, generating approximately $85 million before deductions. 20 March 2026
Pharmaceutical
US biotech Azitra has secured financing of up to $31.4 million, combining an initial $10.5 million raise with a further $20.9 million tied to warrant exercises. The deal is expected to close imminently, pending standard conditions. 20 March 2026
Biotechnology
Montreal, Canada-based Congruence Therapeutics, a clinical-stage, computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, has announced the closing of a $39.5 million financing. 20 March 2026
Biotechnology
Cambridge, USA-based biotech Crossbow Therapeutics, which is developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, today announced it has raised $77 million in a Series B financing. 19 March 2026
Biotechnology
New York, USA-based Ovid Therapeutics closed up 14.4% at $2.30 yesterday, after it announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of $60.0 million to the company, before placement agent fees and offering expenses. 19 March 2026
Biotechnology
Shanghai, China-based biotechnology Excalipoint Therapeutics, which is developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases, today announced an oversubscribed $68.7 million seed financing round to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs. 18 March 2026
Biotechnology
German biotech Kupando has raised an additional 10 million euros ($11 million), bringing its series A total to 23 million euros ($25 million), as it advances its lead candidate KUP101 into early-stage clinical testing. 18 March 2026
Biotechnology
UK biotech Mestag Therapeutics has secured $40 million to fund its first clinical study, as it advances a fibroblast-targeted immunotherapy into human testing. 17 March 2026
Biotechnology
Neuropsychiatric disorders specialist Alto Neuroscience’s shares closed up 8.7% at $24.29 on Monday after the company announced a $120 million private placement led by Commodore Capital with participation from new and existing biotech-focused investors. 17 March 2026
Pharmaceutical
Sovereign wealth funds once appeared only intermittently in life-science financing. Their money surfaced through venture funds or private equity partnerships, usually at one remove from the operating companies themselves. Over the past decade that distance has narrowed, particularly as Gulf investors have become more comfortable deploying capital directly. 16 March 2026
Pharmaceutical
Young British biotech Ternary Therapeutics has raised £3.6 million ($4.6 million) in seed funding to advance an artificial intelligence platform designed to create “molecular glue” drugs, compounds that force two proteins inside cells to bind together and alter disease-driving biology. 16 March 2026
Biotechnology
California, USA based biotech Unnatural Products, which is developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing. 16 March 2026
Pharmaceutical
Chinese radiopharmaceutical startup Eli Radiopharma has secured around 100 million yuan ($14.5 million) in fresh financing as it expands its pipeline and deepens industry partnerships. The Hangzhou-based company said the funds will support target discovery, platform development and clinical translation across oncology and neurological disease programs. 13 March 2026
Pharmaceutical
US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million. The funding was led by Frazier Life Sciences and includes participation from existing investors Atlas Venture, Access Industries and Canaan Partners. 12 March 2026
Biotechnology
Swiss–American biotech CRISPR Therapeutics today announced the pricing of $550 million in convertible senior notes due in 2031. The notes are being offered in a private offering to qualified institutional buyers. 11 March 2026
Pharmaceutical
US clinical-stage biopharma Sling Therapeutics today announced the close of a $123 million Series C financing. The proceeds will support the continued clinical advancement of linsitinib, an oral small molecule inhibitor of IGF-1R (insulin-like growth factor 1 receptor), a validated target for the treatment of thyroid eye disease (TED). 16 September 2026
Biotechnology
California-based biotech company RegCell has closed $66 million in new funding, made up of a $44 million series A led by Playground Global and a further 3.4 billion yen ($22 million) in non-dilutive money from Japan's Agency for Medical Research and Development (AMED). The company said on Tuesday the cash will carry its regulatory T cell platform into clinical development across several autoimmune diseases. 16 September 2026
Generics
Swiss generics and biosimilars company Sandoz has issued a 500 million euros ($585 million) bond with a 12-year maturity and a 4.835% coupon, with proceeds earmarked for general corporate purposes including refinancing existing debt. 15 September 2026
Biotechnology
Electra Therapeutics, a South San Francisco biotech company, has set terms for its stock market debut, proposing to sell 21.7 million shares at between $14 and $16 each. At the $15 midpoint the offering would raise about $325 million and value the business at roughly $916 million. 15 September 2026
Biotechnology
Privately-held US immuno-oncology firm Shennon Biotechnologies has raised $12 million in a financing round from Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures and Saras Capital, with participation from existing investors DCVC, Foundation Capital and AV8 Ventures. 14 September 2026
Pharmaceutical
Swiss pharma major Novartis is under public pressure to overhaul its board after two late-stage trial failures in the space of a few days triggered the steepest share price fall in the company's history. David Samra, managing director at USA-based fund manager Artisan Partners, told Reuters on Thursday that the board needs far stronger oversight of acquisitions. 11 September 2026
Biotechnology
USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. 10 September 2026
Pharmaceutical
US biotech company TwoStep Therapeutics has secured Food and Drug Administration (FDA) clearance to begin human testing of its lead cancer candidate, TS-104, alongside an oversubscribed $62.5 million series A financing. The San Carlos, California-based firm said patient enrollment in a first-in-human Phase I trial should begin before the end of the year. 10 September 2026
Biotechnology
US biotech company Encoded Therapeutics has closed a $275 million series F financing that will fund pivotal testing of ETX101, a gene therapy for Dravet syndrome, a severe form of childhood epilepsy. The privately held South San Francisco firm announced the round on Wednesday, days after presenting updated trial data at the European Epilepsy Congress. 10 September 2026
Biotechnology
US biotech Moonwalk Biosciences, which is developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing. 8 September 2026
Biotechnology
US clinical-stage biotech PDS Biotechnology saw its shares rocket 183% to $0.62 today, after it announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (PIPE) transaction. 8 September 2026
Pharmaceutical
The global pharmaceutical industry has committed an additional £2 billion ($2.70 billion) to the UK since September 2025, according to the Association of the British Pharmaceutical Industry (ABPI), which benchmarks the country against 12 leading markets on more than 40 international metrics in its 2026 competitiveness report. 8 September 2026
Biotechnology
USA-based biotech Superluminal Medicines has closed an oversubscribed $60 million series B, money earmarked for moving its lead obesity candidate into human testing before the end of 2026. The round was led by BVF Partners, with Deep Track Capital and Perceptive Advisors joining as first-time backers. 4 September 2026
Biotechnology
USA-based biotech company Typewriter Therapeutics, which also runs a Japanese arm, came out of stealth on Wednesday with $56 million in series A financing. The round was led by US venture firm AN Venture Partners and US investment firm RA Capital Management, with Japanese venture firm ANRI, Gemseki and SBI US Gateway Fund also taking part. 3 September 2026
Pharmaceutical
The USA's Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to build the equipment needed to make individualized RNA medicines close to the patient, awarding contracts worth up to $125 million in research and development funding. 2 September 2026
Biotechnology
French biotech firm Inventiva has appointed Chris Benecchi as chief operating officer, completing its leadership team roughly one quarter before the trial result that will decide the company's direction. Topline data from the pivotal Phase III NATiV3 study of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) are expected in the final quarter of 2026. 2 September 2026
Biotechnology
USA-based infectious disease biotech firm EIT Pharma has closed an oversubscribed $35 million series A round, led by Propel Bio Partners with participation from Good Ventures, Arrowtown and others. The Kirkland, Washington company said the money will principally support its lead candidate, the oral chronic hepatitis D therapy lonafarnib. 1 September 2026
Pharmaceutical
US specialty pharma company Quoin Pharmaceuticals on Friday said it has entered into a securities purchase agreement to raise up to approximately $50.0 million in gross proceeds. 29 August 2026
Biotechnology
ProFound Therapeutics, a Flagship Pioneering company based in Cambridge, Massachusetts, has received an investment commitment of up to $35 million from the Gates Foundation, including an initial $20 million payment, to support drug target and biomarker discovery for preeclampsia and eclampsia. 28 August 2026
Biotechnology
US biotech major Moderna plans to raise $2 billion through a private placement of convertible senior notes due 2032, offered to qualified institutional buyers under Rule 144A. Initial purchasers will get a 13-day option to take up to $300 million of additional notes, which would lift the total to $2.3 billion. 28 August 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze